Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Depreciation & Amortization (CF) (2023 - 2025)

Bioregenx (BRGX) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $12377.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 97.85% year-over-year to $12377.0; the TTM value through Sep 2025 reached $636597.0, down 61.32%, while the annual FY2024 figure was $2.2 million, 46384.96% up from the prior year.
  • Depreciation & Amortization (CF) reached $12377.0 in Q3 2025 per BRGX's latest filing, down from $37377.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $574466.0 in Q4 2024 and bottomed at $1193.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $207827.0, with a median of $12377.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 48052.98% in 2024, then crashed 97.85% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $1194.0 in 2023, then soared by 48012.73% to $574466.0 in 2024, then crashed by 97.85% to $12377.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $12377.0 in Q3 2025, $37377.0 in Q2 2025, and $12377.0 in Q1 2025.